CLARIFY Registry
•
2 likes•334 views
La Dra. Silvia Valbuena López repasa las conclusiones más relevantes del registro presentado en ESC Congress 2019.
Report
Share
Report
Share
Recommended
Does ESG Investing Work?
ESG investing leads to sustainability and ethical business practices but does ESG investing work when you want to make money? While this way to invest is a positive social force, does ESG investing work to increase your investment assets? Or is it a way to give to charitable causes while being disguised as a way to invest? Will you make money investing this way or would you do better simply giving your money to a cause that you support?
https://youtu.be/YXdOIB5uV_8
E safety safeguarding and risk assessment
This document discusses safeguarding and risk assessment in the learning and skills sector. It defines key terms like risk management, risk assessment, vulnerable adults and children. It explores potential safeguarding risks to learners, staff and organizations like trips, work placements and lone working. It outlines a 5 step process for conducting a risk assessment including identifying risks, who may be harmed, evaluating risk level, recording findings and reviewing assessments. Examples of mitigating risks through measures like supervision and emergency contact arrangements are provided. The document stresses that compliance is the minimum for adequate safeguarding and outlines further safeguarding training available through LSIS.
A Board Perspective on Enterprise Risk Management
This document discusses best practices for enterprise risk management (ERM) from the perspective of a board of directors. It addresses five key dimensions of ERM: risk transparency and insight, risk appetite and strategy, risk-related processes and decisions, risk organization and governance, and risk culture. The document provides recommendations for boards to strengthen their company's risk management, including developing a prioritized risk heat map, understanding the company's "big bets," ensuring risk reports deliver clear and insightful information, defining the company's risk appetite, integrating risk insights into strategy, and focusing on building a strong risk culture. The document concludes by outlining 12 specific actions boards should take to lift their company to the highest standards of risk management.
Powering Your ESG Ambitions WIth Data
This document summarizes a webinar on powering ESG ambitions through data. It discusses how ESG reporting is challenging due to different standards and data sources, but that a targeted data strategy can help. It recommends starting with cataloging ESG data, selecting key stakeholder dimensions, targeting a maturity level, building a data sandbox, and creating a community of practice to embark on an ESG journey through data. The webinar emphasizes that ESG is both urgent and important given regulatory demands, consumer expectations, and how financial markets are increasingly considering ESG metrics.
Esg 2020 slides
Institutional investors are increasingly adopting ESG investing on a global scale. A survey of over 500 institutional investors found that more than half now fully integrate ESG into their investment approach, up from 36% in 2019. Motivations for ESG investing include obtaining better risk-adjusted returns and risk management. However, concerns around "greenwashing" where companies only pay lip service to ESG issues remain high. The lack of clear evidence linking ESG performance to financial performance also poses a barrier to greater ESG adoption.
The next step in ESG Integration - Refinitiv
Refinitiv enables tailored integration of ESG into the research, investment vehicle creation, and investment management processes through audible, standardized data across all Environmental, Social and Governance pillars, transparent and customizable rating mechanism, and regularly updating controversies. Refinitiv provides a wide range of concorded historic and forward looking fundamental and pricing data, and value-add index calculation services supporting thematic investments. Refinitiv aims to be the next step in ESG Integration.
ESG seminar
The document discusses an energy company's efforts to reduce emissions and enable the transition to a lower carbon future. It outlines the company's commitment to achieving net zero emissions by 2040 for Scope 1 and 2 emissions. It also details various initiatives to reduce methane leaks from pipelines and other infrastructure, increase the efficiency of compressor stations, and ensure assets are ready to transport hydrogen and other renewable gases. The company is working with suppliers and international partners to reduce Scope 3 emissions and promote decarbonization across its value chain.
Recommended
Does ESG Investing Work?
ESG investing leads to sustainability and ethical business practices but does ESG investing work when you want to make money? While this way to invest is a positive social force, does ESG investing work to increase your investment assets? Or is it a way to give to charitable causes while being disguised as a way to invest? Will you make money investing this way or would you do better simply giving your money to a cause that you support?
https://youtu.be/YXdOIB5uV_8
E safety safeguarding and risk assessment
This document discusses safeguarding and risk assessment in the learning and skills sector. It defines key terms like risk management, risk assessment, vulnerable adults and children. It explores potential safeguarding risks to learners, staff and organizations like trips, work placements and lone working. It outlines a 5 step process for conducting a risk assessment including identifying risks, who may be harmed, evaluating risk level, recording findings and reviewing assessments. Examples of mitigating risks through measures like supervision and emergency contact arrangements are provided. The document stresses that compliance is the minimum for adequate safeguarding and outlines further safeguarding training available through LSIS.
A Board Perspective on Enterprise Risk Management
This document discusses best practices for enterprise risk management (ERM) from the perspective of a board of directors. It addresses five key dimensions of ERM: risk transparency and insight, risk appetite and strategy, risk-related processes and decisions, risk organization and governance, and risk culture. The document provides recommendations for boards to strengthen their company's risk management, including developing a prioritized risk heat map, understanding the company's "big bets," ensuring risk reports deliver clear and insightful information, defining the company's risk appetite, integrating risk insights into strategy, and focusing on building a strong risk culture. The document concludes by outlining 12 specific actions boards should take to lift their company to the highest standards of risk management.
Powering Your ESG Ambitions WIth Data
This document summarizes a webinar on powering ESG ambitions through data. It discusses how ESG reporting is challenging due to different standards and data sources, but that a targeted data strategy can help. It recommends starting with cataloging ESG data, selecting key stakeholder dimensions, targeting a maturity level, building a data sandbox, and creating a community of practice to embark on an ESG journey through data. The webinar emphasizes that ESG is both urgent and important given regulatory demands, consumer expectations, and how financial markets are increasingly considering ESG metrics.
Esg 2020 slides
Institutional investors are increasingly adopting ESG investing on a global scale. A survey of over 500 institutional investors found that more than half now fully integrate ESG into their investment approach, up from 36% in 2019. Motivations for ESG investing include obtaining better risk-adjusted returns and risk management. However, concerns around "greenwashing" where companies only pay lip service to ESG issues remain high. The lack of clear evidence linking ESG performance to financial performance also poses a barrier to greater ESG adoption.
The next step in ESG Integration - Refinitiv
Refinitiv enables tailored integration of ESG into the research, investment vehicle creation, and investment management processes through audible, standardized data across all Environmental, Social and Governance pillars, transparent and customizable rating mechanism, and regularly updating controversies. Refinitiv provides a wide range of concorded historic and forward looking fundamental and pricing data, and value-add index calculation services supporting thematic investments. Refinitiv aims to be the next step in ESG Integration.
ESG seminar
The document discusses an energy company's efforts to reduce emissions and enable the transition to a lower carbon future. It outlines the company's commitment to achieving net zero emissions by 2040 for Scope 1 and 2 emissions. It also details various initiatives to reduce methane leaks from pipelines and other infrastructure, increase the efficiency of compressor stations, and ensure assets are ready to transport hydrogen and other renewable gases. The company is working with suppliers and international partners to reduce Scope 3 emissions and promote decarbonization across its value chain.
COVID-19 Vaccination in Patients Requiring Palliative Care
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr. Richard Lim Boon Leong is a Consultant Palliative Medicine Physician and Head of Palliative Care Unit, Selayang Hospital, Ministry of Health Malaysia.
Mixed results for heart failure therapies, journel club
1. A study compared the angiotensin receptor–neprilysin inhibitor LCZ696 to enalapril in patients with heart failure and reduced ejection fraction. LCZ696 was superior to enalapril in reducing risks of death and hospitalization for heart failure.
2. A trial investigated spironolactone in patients with heart failure and preserved ejection fraction. Spironolactone did not significantly reduce the primary outcome but did lower the risk of hospitalization for heart failure. It increased hyperkalemia but with monitoring, serious adverse events were similar to placebo.
3. A study examined intravenous ferric carboxymaltose in patients with heart failure, reduced
BLOCK HF trial
The document summarizes several studies on cardiac resynchronization therapy (CRT) for heart failure. The Block HF trial found that CRT was superior to right ventricular pacing alone in reducing death and heart failure-related events in patients with heart failure, left ventricular dysfunction, and AV block. Subsequent trials like COMPANION, CARE-HF, REVERSE, and MADIT-CRT also demonstrated benefits of CRT over medical therapy alone in improving outcomes like mortality, hospitalizations, quality of life and left ventricular function. Updated guidelines have expanded the use of CRT to patients in NYHA class I/II with left bundle branch block and QRS duration over 150ms.
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
This document provides information on new guidelines and therapies for heart failure patients. It begins by outlining the challenges of managing heart failure patients and their high mortality rates. It then discusses the history of heart failure treatments from ACE inhibitors in the 1990s to newer drugs like ARNi's. The document defines the different types of heart failure - HFrEF, HFmrEF, and HFpEF - and their diagnostic criteria. It explains how neprilysin inhibition enhances natriuretic peptides while simultaneously suppressing the RAAS. Finally, it summarizes that the new drug LCZ696 combines neprilysin inhibition with an ARB to reduce mortality and hospitalization in heart failure patients beyond existing neurohormonal therapies
[Paper Report] Coronary Artery Bypass Graft versus Percutaneous Coronary In...
CABG was associated with lower long-term mortality compared to PCI in patients with acute heart failure and coronary artery disease. The study analyzed 717 patients hospitalized for acute heart failure who received either CABG or PCI. Patients who received CABG had lower rates of all-cause death after discharge and revascularization compared to PCI. CABG was also associated with fewer rehospitalizations for cardiovascular issues. However, the study was limited by its observational design and inability to fully account for differences in patient characteristics between treatment groups.
20181210 noon conference - Milligan
- The patient presented with superior vena cava syndrome and was found to have elevated lactate dehydrogenase and extensive lymphadenopathy on CT scan. Biopsy of a mediastinal mass revealed diffuse large B-cell lymphoma (DLBCL).
- Key results included elevated LDH and CT findings of lymphadenopathy concerning for lymphoma. Biopsy confirmed DLBCL which commonly presents as a rapidly enlarging mass and was the cause of the patient's superior vena cava syndrome.
- The patient was diagnosed with Stage IIB DLBCL and received R-EPOCH chemotherapy as the primary treatment.
Chronic Coronary Syndrome ESC 2019.pptx
Chronic coronary syndrome (CCS) is a term that defines coronary artery disease as a chronic progressive course. It has been introduced to replace the previous term ‘stable coronary artery disease’.
HEMODYNAMICS & NATURAL HISTORY OF PS.pptx
1. Congenital pulmonary stenosis can range from mild to critical severity depending on the right ventricular pressure and pressure gradient across the pulmonary valve.
2. For mild pulmonary stenosis, the natural history is benign and no intervention is typically needed. Moderate stenosis may progress during periods of growth and intervention is considered for gradients over 40-50 mmHg.
3. Balloon valvuloplasty is now the standard intervention for pulmonary stenosis and provides good long-term outcomes, though 20-30% of patients may require an additional procedure.
Heart failure
This document discusses heart failure management in primary care. It begins with a case presentation of a 66-year-old woman with shortness of breath and leg edema. Examination findings are provided. It then discusses classic heart failure management including diuretics, ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists. New management options discussed include sacubitril/valsartan and ivabradine. Referral indications provided include worsening symptoms, arrhythmias, and consideration for transplantation.
Cardiology Journal scan
In this ppt i am going to discuss regarding two important paper published in Journal of American college of cardiology in May, June 2017.
Atrial Fibrillation-Detection and management
Atrial Fibrillation is the most common arrhythmia encountered by a physician. The global prevalence is increasing because of aging population and better detection methods. Prediction of new onset AF is possible. AF is also a lifestyle disease. Lifestyle therapy, rate or rhythm control and stroke risk stratification are are four main pillars of AF management.
Pbmv tips and tricks
The document provides information on percutaneous balloon mitral valvuloplasty (PBMV) for the treatment of mitral stenosis. It discusses the epidemiology and natural history of rheumatic heart disease and mitral stenosis. PBMV is recommended for symptomatic patients with moderate to severe mitral stenosis who have favorable valve morphology and no significant mitral regurgitation or left atrial thrombus. Echocardiography is important for assessing valve anatomy and ruling out contraindications prior to the procedure. The goal of PBMV is to safely and effectively dilate the mitral valve and relieve obstruction while avoiding complications such as mitral regurgitation or cardiac tamponade. Younger patients with pliable
Revisiting Pulmonary embolism Guidelines
Pulmonary embolism (PE) is a blockage in one of the pulmonary arteries in the lungs. The document discusses guidelines and considerations for diagnosing and treating PE. It provides details on:
- Symptoms of PE like shortness of breath and signs like tachycardia.
- Using clinical prediction rules like the Wells criteria to determine pre-test probability and decide on testing.
- Tests like CT scans, VQ scans, and echocardiograms to diagnose PE.
- Risk stratifying patients as low, intermediate, or high risk to guide treatment decisions.
- Initial treatment with anticoagulants like heparin or newer oral medications.
- Long term treatment and
Early initiation of ARNI in ADHF - final.pptx
- ARNI (angiotensin receptor-neprilysin inhibitor) drugs like sacubitril/valsartan work by inhibiting neprilysin, which breaks down natriuretic peptides, leading to increased levels of natriuretic peptides that can reduce blood pressure and cardiac remodeling.
- Evidence shows ARNI drugs are effective in reducing hospitalizations and mortality in chronic heart failure patients with reduced ejection fraction. However, their role in acute decompensated heart failure is still being investigated.
- Ongoing studies are exploring if early initiation of ARNI after admission for acute decompensated heart failure can help prevent cardiac remodeling and readmissions compared to initiating ARNI only after stabilization.
Chronic coronary syndromes
1. Chronic coronary syndromes (CCS) refer to conditions involving atherosclerotic plaque buildup in the coronary arteries that can cause various clinical presentations depending on the dynamic nature of the disease process.
2. The most common clinical scenarios in patients with suspected or established CCS involve those with stable angina symptoms, new onset of heart failure, recent acute coronary syndrome, or asymptomatic patients more than 1 year after initial diagnosis or revascularization.
3. Evaluation and management of patients with suspected CCS involves assessing symptoms, risk factors and comorbidities, performing basic testing, estimating pre-test probability of CAD, selecting appropriate non-invasive testing to confirm diagnosis when needed, calculating risk, and determining long-
Sickle Presentation.ppt
This document summarizes a study on deaths related to haemoglobinopathies in the UK from 2005-2006. It reviewed 47 cases and aimed to identify remediable factors in patient care. Key findings included a lack of understanding about sickle cell trait, inconsistent vaccination records, irregular outpatient attendance, and issues with both ongoing and acute pain management including opioid overdoses. Causes of death included stroke, acute chest syndrome, and renal failure, where timely recognition and management could have made a difference. The study made recommendations around improving protocols, guidelines, multi-disciplinary care, and clinician education about haemoglobinopathies.
Natural history and treatment of aortic stenosis
This document discusses the natural history and treatment of aortic stenosis. It defines the severity classifications based on aortic jet velocity, mean gradient, and valve area. Symptoms rarely occur with severe aortic stenosis if left ventricular function is normal. The document reviews progression rates in asymptomatic patients and risk factors for more rapid progression. Exercise testing may help identify higher risk asymptomatic patients but is not routinely recommended. Biomarkers like BNP levels can also predict outcomes. The prognosis is poor once patients become symptomatic, so surgical intervention is recommended for symptomatic severe aortic stenosis.
Diabetes and heart two sides of the same coin
This ppt presented in a CME of doctors in March 2017 discusses-if all Diabetics should be treated aggressively for prevention of coronary artery disease & SHOULD IT BE PRESUMED AS IF THEY ARE ALREADY PATIENTS OF CAD?
This presentation is updated till March 2017
Lupus nephritis update Ahmed Yehia
Lupus nephritis update Ahmed YehiaInternal medicine department, faculty of Medicine Beni-Suef University Egypt
Lupus nephritis update, classification, approach according to guidelines, different case scenarios with stress on algorithmic management of different presentations
Ahmed YehiaEVALUATION OF ATRIAL FIBRILLATION-1.pdf
Afib stands for atrial fibrillation (AF), which is a type of arrhythmia, or abnormal heartbeat. Afib is caused by extremely fast and irregular beats from the upper chambers of the heart (usually more than 400 beats per minute). A normal, healthy heartbeat involves a regular contraction of the heart muscle
Hazte socio de la Sociedad Española de Cardiología
La Sociedad Española de Cardiología (SEC) es una organización científica sin ánimo de lucro con la misión de reducir el impacto adverso de las enfermedades cardiovasculares y promover una mejor salud cardiovascular en la ciudadanía.
Identificación del paciente con alto riesgo tras SCA reciente
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
More Related Content
Similar to CLARIFY Registry
COVID-19 Vaccination in Patients Requiring Palliative Care
Webinar Series on COVID-19 vaccine: Jointly organized by Malaysian Society of Infection Control and Infectious Diseases (MyICID) & Institute for Clinical Research (ICR), NIH
Speaker: Dr. Richard Lim Boon Leong is a Consultant Palliative Medicine Physician and Head of Palliative Care Unit, Selayang Hospital, Ministry of Health Malaysia.
Mixed results for heart failure therapies, journel club
1. A study compared the angiotensin receptor–neprilysin inhibitor LCZ696 to enalapril in patients with heart failure and reduced ejection fraction. LCZ696 was superior to enalapril in reducing risks of death and hospitalization for heart failure.
2. A trial investigated spironolactone in patients with heart failure and preserved ejection fraction. Spironolactone did not significantly reduce the primary outcome but did lower the risk of hospitalization for heart failure. It increased hyperkalemia but with monitoring, serious adverse events were similar to placebo.
3. A study examined intravenous ferric carboxymaltose in patients with heart failure, reduced
BLOCK HF trial
The document summarizes several studies on cardiac resynchronization therapy (CRT) for heart failure. The Block HF trial found that CRT was superior to right ventricular pacing alone in reducing death and heart failure-related events in patients with heart failure, left ventricular dysfunction, and AV block. Subsequent trials like COMPANION, CARE-HF, REVERSE, and MADIT-CRT also demonstrated benefits of CRT over medical therapy alone in improving outcomes like mortality, hospitalizations, quality of life and left ventricular function. Updated guidelines have expanded the use of CRT to patients in NYHA class I/II with left bundle branch block and QRS duration over 150ms.
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
This document provides information on new guidelines and therapies for heart failure patients. It begins by outlining the challenges of managing heart failure patients and their high mortality rates. It then discusses the history of heart failure treatments from ACE inhibitors in the 1990s to newer drugs like ARNi's. The document defines the different types of heart failure - HFrEF, HFmrEF, and HFpEF - and their diagnostic criteria. It explains how neprilysin inhibition enhances natriuretic peptides while simultaneously suppressing the RAAS. Finally, it summarizes that the new drug LCZ696 combines neprilysin inhibition with an ARB to reduce mortality and hospitalization in heart failure patients beyond existing neurohormonal therapies
[Paper Report] Coronary Artery Bypass Graft versus Percutaneous Coronary In...
CABG was associated with lower long-term mortality compared to PCI in patients with acute heart failure and coronary artery disease. The study analyzed 717 patients hospitalized for acute heart failure who received either CABG or PCI. Patients who received CABG had lower rates of all-cause death after discharge and revascularization compared to PCI. CABG was also associated with fewer rehospitalizations for cardiovascular issues. However, the study was limited by its observational design and inability to fully account for differences in patient characteristics between treatment groups.
20181210 noon conference - Milligan
- The patient presented with superior vena cava syndrome and was found to have elevated lactate dehydrogenase and extensive lymphadenopathy on CT scan. Biopsy of a mediastinal mass revealed diffuse large B-cell lymphoma (DLBCL).
- Key results included elevated LDH and CT findings of lymphadenopathy concerning for lymphoma. Biopsy confirmed DLBCL which commonly presents as a rapidly enlarging mass and was the cause of the patient's superior vena cava syndrome.
- The patient was diagnosed with Stage IIB DLBCL and received R-EPOCH chemotherapy as the primary treatment.
Chronic Coronary Syndrome ESC 2019.pptx
Chronic coronary syndrome (CCS) is a term that defines coronary artery disease as a chronic progressive course. It has been introduced to replace the previous term ‘stable coronary artery disease’.
HEMODYNAMICS & NATURAL HISTORY OF PS.pptx
1. Congenital pulmonary stenosis can range from mild to critical severity depending on the right ventricular pressure and pressure gradient across the pulmonary valve.
2. For mild pulmonary stenosis, the natural history is benign and no intervention is typically needed. Moderate stenosis may progress during periods of growth and intervention is considered for gradients over 40-50 mmHg.
3. Balloon valvuloplasty is now the standard intervention for pulmonary stenosis and provides good long-term outcomes, though 20-30% of patients may require an additional procedure.
Heart failure
This document discusses heart failure management in primary care. It begins with a case presentation of a 66-year-old woman with shortness of breath and leg edema. Examination findings are provided. It then discusses classic heart failure management including diuretics, ACE inhibitors, ARBs, beta-blockers, and aldosterone antagonists. New management options discussed include sacubitril/valsartan and ivabradine. Referral indications provided include worsening symptoms, arrhythmias, and consideration for transplantation.
Cardiology Journal scan
In this ppt i am going to discuss regarding two important paper published in Journal of American college of cardiology in May, June 2017.
Atrial Fibrillation-Detection and management
Atrial Fibrillation is the most common arrhythmia encountered by a physician. The global prevalence is increasing because of aging population and better detection methods. Prediction of new onset AF is possible. AF is also a lifestyle disease. Lifestyle therapy, rate or rhythm control and stroke risk stratification are are four main pillars of AF management.
Pbmv tips and tricks
The document provides information on percutaneous balloon mitral valvuloplasty (PBMV) for the treatment of mitral stenosis. It discusses the epidemiology and natural history of rheumatic heart disease and mitral stenosis. PBMV is recommended for symptomatic patients with moderate to severe mitral stenosis who have favorable valve morphology and no significant mitral regurgitation or left atrial thrombus. Echocardiography is important for assessing valve anatomy and ruling out contraindications prior to the procedure. The goal of PBMV is to safely and effectively dilate the mitral valve and relieve obstruction while avoiding complications such as mitral regurgitation or cardiac tamponade. Younger patients with pliable
Revisiting Pulmonary embolism Guidelines
Pulmonary embolism (PE) is a blockage in one of the pulmonary arteries in the lungs. The document discusses guidelines and considerations for diagnosing and treating PE. It provides details on:
- Symptoms of PE like shortness of breath and signs like tachycardia.
- Using clinical prediction rules like the Wells criteria to determine pre-test probability and decide on testing.
- Tests like CT scans, VQ scans, and echocardiograms to diagnose PE.
- Risk stratifying patients as low, intermediate, or high risk to guide treatment decisions.
- Initial treatment with anticoagulants like heparin or newer oral medications.
- Long term treatment and
Early initiation of ARNI in ADHF - final.pptx
- ARNI (angiotensin receptor-neprilysin inhibitor) drugs like sacubitril/valsartan work by inhibiting neprilysin, which breaks down natriuretic peptides, leading to increased levels of natriuretic peptides that can reduce blood pressure and cardiac remodeling.
- Evidence shows ARNI drugs are effective in reducing hospitalizations and mortality in chronic heart failure patients with reduced ejection fraction. However, their role in acute decompensated heart failure is still being investigated.
- Ongoing studies are exploring if early initiation of ARNI after admission for acute decompensated heart failure can help prevent cardiac remodeling and readmissions compared to initiating ARNI only after stabilization.
Chronic coronary syndromes
1. Chronic coronary syndromes (CCS) refer to conditions involving atherosclerotic plaque buildup in the coronary arteries that can cause various clinical presentations depending on the dynamic nature of the disease process.
2. The most common clinical scenarios in patients with suspected or established CCS involve those with stable angina symptoms, new onset of heart failure, recent acute coronary syndrome, or asymptomatic patients more than 1 year after initial diagnosis or revascularization.
3. Evaluation and management of patients with suspected CCS involves assessing symptoms, risk factors and comorbidities, performing basic testing, estimating pre-test probability of CAD, selecting appropriate non-invasive testing to confirm diagnosis when needed, calculating risk, and determining long-
Sickle Presentation.ppt
This document summarizes a study on deaths related to haemoglobinopathies in the UK from 2005-2006. It reviewed 47 cases and aimed to identify remediable factors in patient care. Key findings included a lack of understanding about sickle cell trait, inconsistent vaccination records, irregular outpatient attendance, and issues with both ongoing and acute pain management including opioid overdoses. Causes of death included stroke, acute chest syndrome, and renal failure, where timely recognition and management could have made a difference. The study made recommendations around improving protocols, guidelines, multi-disciplinary care, and clinician education about haemoglobinopathies.
Natural history and treatment of aortic stenosis
This document discusses the natural history and treatment of aortic stenosis. It defines the severity classifications based on aortic jet velocity, mean gradient, and valve area. Symptoms rarely occur with severe aortic stenosis if left ventricular function is normal. The document reviews progression rates in asymptomatic patients and risk factors for more rapid progression. Exercise testing may help identify higher risk asymptomatic patients but is not routinely recommended. Biomarkers like BNP levels can also predict outcomes. The prognosis is poor once patients become symptomatic, so surgical intervention is recommended for symptomatic severe aortic stenosis.
Diabetes and heart two sides of the same coin
This ppt presented in a CME of doctors in March 2017 discusses-if all Diabetics should be treated aggressively for prevention of coronary artery disease & SHOULD IT BE PRESUMED AS IF THEY ARE ALREADY PATIENTS OF CAD?
This presentation is updated till March 2017
Lupus nephritis update Ahmed Yehia
Lupus nephritis update Ahmed YehiaInternal medicine department, faculty of Medicine Beni-Suef University Egypt
Lupus nephritis update, classification, approach according to guidelines, different case scenarios with stress on algorithmic management of different presentations
Ahmed YehiaEVALUATION OF ATRIAL FIBRILLATION-1.pdf
Afib stands for atrial fibrillation (AF), which is a type of arrhythmia, or abnormal heartbeat. Afib is caused by extremely fast and irregular beats from the upper chambers of the heart (usually more than 400 beats per minute). A normal, healthy heartbeat involves a regular contraction of the heart muscle
Similar to CLARIFY Registry (20)
COVID-19 Vaccination in Patients Requiring Palliative Care
COVID-19 Vaccination in Patients Requiring Palliative Care
Mixed results for heart failure therapies, journel club
Mixed results for heart failure therapies, journel club
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
Guidelines and beyond new drug therapy for heart failure with reduced ejectio...
[Paper Report] Coronary Artery Bypass Graft versus Percutaneous Coronary In...
[Paper Report] Coronary Artery Bypass Graft versus Percutaneous Coronary In...
More from Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de Cardiología
La Sociedad Española de Cardiología (SEC) es una organización científica sin ánimo de lucro con la misión de reducir el impacto adverso de las enfermedades cardiovasculares y promover una mejor salud cardiovascular en la ciudadanía.
Identificación del paciente con alto riesgo tras SCA reciente
Ponencia presentada por la Dra. Marisol Bravo Amaro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del Corazón
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Sociedad Española de Cardiología
Ponencia presentada por el Dr. Armando Oterino Manzanas en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del CorazónDebatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...Sociedad Española de Cardiología
Ponencia presentada por la Dra. Miriam Martín Toro en el CardioTV Live ‘Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome coronario agudo reciente’, realizado el 21 de mayo de 2024 en la Casa del CorazónProyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...Sociedad Española de Cardiología
Ponencia presentada por los Dres. M.ª Dolores Mesa Rubio, Javier Mora Robles, Margarita Reina Sánchez, M.ª José Castillo Moraga y José Luis Bianchi Llave en el CardioTV Focus, publicado el 25 de abril de 2024 en la Casa del Corazón (Madrid).Estudio IVUS-ACS
La Dra. Neus Salvatella Giralt comenta los resultados del estudio IVUS-ACS, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio PREVENT
La Dra. Neus Salvatella Giralt comenta los resultados del estudio PREVENT, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio DEDICATE-DZHK6
La Dra. Neus Salvatella Giralt comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio TRAVERSE
La Dra. Júlia Aranyó Llach comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio FULL-REVASC
El Dr. Borja Rivero Santana comenta los resultados del estudio FULL-REVASC presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio IMPROVE-HCM
La Dra. Júlia Aranyó Llach comenta los resultados del estudio IMPROVE-HCM, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio ORBITA-COSMIC
El Dr. Borja Rivero Santana comenta los resultados del estudio ORBITA-COSMIC, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio ARISE-HF
La Dra. Júlia Aranyó Llach comenta los resultados del estudio ARISE-HF, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio TACTiC
El Dr. Koldo Ugedo Alzaga comenta los resultados del estudio TACTiC, presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio ULTIMATE DAPT
La Dra. Neus Salvatella Giralt comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio SHASTA-2
El Dr. Koldo Ugedo Alzaga comenta los resultados del estudio SHASTA-2 presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio MINT
La Dra. Júlia Aranyó Llach comenta los resultados del estudio MINT presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisiránSociedad Española de Cardiología
El Dr. Koldo Ugedo Alzaga comenta los resultados del estudio presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).Estudio SMART
La Dra. Neus Salvatella Giralt comenta los resultados del estudio SMART presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
Estudio REDUCE-AMI
La Dra. Neus Salvatella Giralt comenta los resultados del estudio REDUCE-AMI presentado en ACC Congress 2024, celebrado en Atlanta (9-8 abril).
More from Sociedad Española de Cardiología (20)
Hazte socio de la Sociedad Española de Cardiología
Hazte socio de la Sociedad Española de Cardiología
Identificación del paciente con alto riesgo tras SCA reciente
Identificación del paciente con alto riesgo tras SCA reciente
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Debatiendo estrategias actuales para la reducción de eventos CV tras síndrome...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
Proyecto FARO. Prevención secundaria de la enfermedad cardiovascular ateroscl...
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
ePóster. Reducciones c-LDL el primer año de tratamiento con inclisirán
Recently uploaded
10 Benefits an EPCR Software should Bring to EMS Organizations
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis is an increasing cause of morbidity among the elderly.
In this document , a brief outline of osteoporosis is given , including the risk factors of osteoporosis fractures , the indications for testing bone mineral density and the management of osteoporosis
Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff offers comprehensive travel health services, including vaccinations, travel advice, and preventive care for international travelers. Our expert team ensures you are well-prepared and protected for your journey, providing personalized consultations tailored to your destination. Conveniently located in Cardiff, we help you travel with confidence and peace of mind. Visit us: www.nxhealthcare.co.uk
Efficacy of Avartana Sneha in Ayurveda
Avartana Sneha is a unique method of Preparation of Sneha Kalpana in Ayurveda, mainly it is indicated for the Vataja rogas.
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Adhd Medication Shortage Uk - trinexpharmacy.com
The UK is currently facing a Adhd Medication Shortage Uk, which has left many patients and their families grappling with uncertainty and frustration. ADHD, or Attention Deficit Hyperactivity Disorder, is a chronic condition that requires consistent medication to manage effectively. This shortage has highlighted the critical role these medications play in the daily lives of those affected by ADHD. Contact : +1 (747) 209 – 3649 E-mail : sales@trinexpharmacy.com
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
vonoprazan A novel drug for GERD presentation
Vonoprazan, a new potassium acid channel blocker used in the conditions of GERD and gastric ulcer, duodenal ulcer ....
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
This quiz was conducted as a promotional event for the 2024 Annual Meet of Kerala Chapter of API.
More than 20 participants took part everyday !
DECLARATION OF HELSINKI - History and principles
This SlideShare presentation provides a comprehensive overview of the Declaration of Helsinki, a foundational document outlining ethical guidelines for conducting medical research involving human subjects.
Histololgy of Female Reproductive System.pptx
Dive into an in-depth exploration of the histological structure of female reproductive system with this comprehensive lecture. Presented by Dr. Ayesha Irfan, Assistant Professor of Anatomy, this presentation covers the Gross anatomy and functional histology of the female reproductive organs. Ideal for students, educators, and anyone interested in medical science, this lecture provides clear explanations, detailed diagrams, and valuable insights into female reproductive system. Enhance your knowledge and understanding of this essential aspect of human biology.
Recently uploaded (20)
10 Benefits an EPCR Software should Bring to EMS Organizations
10 Benefits an EPCR Software should Bring to EMS Organizations
Osteoporosis - Definition , Evaluation and Management .pdf
Osteoporosis - Definition , Evaluation and Management .pdf
Outbreak management including quarantine, isolation, contact.pptx
Outbreak management including quarantine, isolation, contact.pptx
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
Travel Clinic Cardiff: Health Advice for International Travelers
Travel Clinic Cardiff: Health Advice for International Travelers
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
pathology MCQS introduction to pathology general pathology
pathology MCQS introduction to pathology general pathology
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
CLARIFY Registry
- 1. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS Eur Heart J. doi:10.1093/eurheartj/ehz660 CLARIFY - IN STABLE CORONARY DISEASE, PATIENTS WITH ANGINA AND PRIOR MYOCARDIAL INFARCTION HAVE A POOR PROGNOSIS DESPITE ADHERENCE TO GUIDELINE RECOMMENDED THERAPIES. FINAL 5-YEAR RESULTS FROM THE CLARIFY STUDY
- 2. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS
- 3. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS AIMS 1.- To describe demographics, clinical characteristics, and management of patients with chronic coronary syndromes 2.- To assess the rates and determinants of outcomes in patients with chronic coronary syndromes
- 4. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS • Prospective longitudinal observational registry of patients with stable coronary disease • N 32703 patients from 45 countries. • Nov 2009-June 2010. Database lock 2016 • Yearly visit. Median follow-up 5 years • Inclusion criteria - Prior MI > 3 months - Prior revascularization > 3 months - Proven symptomatic myocardial ischaemia - Angiographic coronary artery stenosis >50% METHODS
- 5. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS BASELINE CHARACTERISTICS
- 6. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS BASELINE CHARACTERISTICS
- 7. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS PRIMARY AND SECONDARY OUTCOMES
- 8. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS PREDICTORS OF PRIMARY OUTCOME
- 9. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS 5-YEAR INCIDENCE OF CV DEATH AND MI
- 10. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS LIMITACIONES • 45 countries, but no USA. In Africa only South Africa • Majority of patients with prior MI (≈ 60%) post MI patients rather than chronic coronary síndromes • Only 22,% has angina (disease previously known as stable angina) • Anginal symptoms only reported at baseline but 5-year follow-up
- 11. Silvia Valbuena LópezCLARIFY: FINAL 5-YEAR RESULTS CONCLUSIONES La incidencia de muerte CV e IAM fue de 1.7 por 100 paciente-año, menor que la descrita en otros registros La angina fue un parámetro pronóstico solamente entre los pacientes con IAM previo Los pacientes con angina e IAM previo constituyen un grupo de riesgo aumentado que requieren optimización máxima del tratamiento médico